Sublingual immunotherapy in southern Africa: lessons learned.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23587331.
- Also identified by DOI 10.1016/j.jaci.2013.02.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sublingual immunotherapy (SLIT) is recommended in South Africa for the treatment of allergic rhinitis (with or without asthma) to house dust mites or grass pollens. Recent local studies have confirmed efficacy and safety but have also shown heterogeneity in clinical responses to the European SLIT vaccines used in the region. It has been found that regular follow-up with standardized rhinitis quality-of-life questionnaires improves compliance and encourages the patients to complete the 3-year SLIT course. Patients who discontinue usually do so in the first year because of logistic and financial reasons rather than adverse side effects. Further studies are in progress at the Allergy Diagnostic & Clinical Research Unit to identify immunologic markers of the SLIT responder phenotype.
Medical subject headings
- Desensitization, Immunologic
- Rhinitis, Allergic, Perennial